Clinical Observation of Entecavir in the Treatment of Decompensated Cirrhotic Patient with HBV for 96 Weeks

Objective To observe the curative efficacy, YMDD mutation and safety of entecavir treated Hepatitis B patients with decompensated cirrhosis. Methods 57 patients from our hospital from March 2006 to June 2009, were randomLy divided into two groups. 28 patients in group A were treated with lamivudine 100mg/d, and 29 patients in group B were treated with entecavir 0.5mg/d. They also received living-protecting, and the other symptomatic treatments. The total treatment in these two groups was 96 weeks. The level of HBV DNA, Child-Pugh score, YMDD mutation and adverse drug reactions were detected detailed. Results After the treatment, there were obvious undetectable rate of HBV DNA and improved Child Pugh score in the two groups. But the comparisons have no statistical difference(P0.05). YMDD mutation would appear at 48 weeks in group A which used lamivudine 100mg/d for treatment. And the greater variation would come out as the time become longer. There was no YMDD mutation in group B at the total treatment. YMDD variation had significant differences between the two groups at 72 weeks (P0.05). Two groups have no medicine related serious untoward effect occurred. Conclusion Entecavir treatments in patients with decompensate hepatitis B cirrhosis 96 weeks, its efficacy and safety of lamivudine were similar, but significantly reduced the incidence of YMDD mutation. Entecavir is an effective and ideal treatment of decompensate liver cirrhosis drug.